15.99
price down icon0.41%   -0.010
after-market 시간 외 거래: 15.99
loading
전일 마감가:
$16.00
열려 있는:
$16.01
하루 거래량:
20,623
Relative Volume:
0.67
시가총액:
$210.76M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.71%
1개월 성능:
-14.10%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
Value
$15.47
$16.15
1주일 범위
Value
$14.71
$16.91
52주 변동 폭
Value
$14.71
$19.40

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name
명칭
Onkure Therapeutics Inc
Name
전화
(720) 307-2892
Name
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
OKUR's Discussions on Twitter

OKUR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
OKUR 15.99 210.76M 0 0 0 0.00
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스

pulisher
Nov 20, 2024

OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth - MSN

Nov 20, 2024
pulisher
Nov 14, 2024

OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis - Defense World

Nov 14, 2024
pulisher
Nov 09, 2024

OnKure Therapeutics' (OKUR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 09, 2024
pulisher
Nov 07, 2024

OnKure Therapeutics announces accounting firm change - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Form 424B3 OnKure Therapeutics, - StreetInsider.com

Nov 07, 2024
pulisher
Nov 07, 2024

Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 05, 2024

OnKure to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire

Nov 05, 2024
pulisher
Nov 01, 2024

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire

Nov 01, 2024
pulisher
Oct 25, 2024

VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure - Investing.com

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics Faces License Agreement Termination - TipRanks

Oct 25, 2024
pulisher
Oct 24, 2024

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha

Oct 24, 2024
pulisher
Oct 21, 2024

Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat

Oct 21, 2024
pulisher
Oct 19, 2024

Analysts Offer Predictions for OKUR Q1 Earnings - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

What is HC Wainwright's Estimate for OKUR Q1 Earnings? - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

HC Wainwright Reiterates Buy Rating for OnKure Therapeutics (NASDAQ:OKUR) - MarketBeat

Oct 17, 2024
pulisher
Oct 14, 2024

OnKure Therapeutics (OKUR) Stock Rebounds In Extended Session - Stocks Telegraph

Oct 14, 2024
pulisher
Oct 11, 2024

OnKure started at outperform by Oppenheimer, OKI-219 potential cited - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

OnKure shares initiated with Outperform rating on drug potential - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

OnKure shares initiated with Outperform rating on drug potential By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 10, 2024

This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 10, 2024
pulisher
Oct 08, 2024

Reneo Pharmaceuticals Completes Merger and Name Change to OnKure Therapeutics, Inc. - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Newley merged OnKure raises $65 million - The Pharma Letter

Oct 08, 2024
pulisher
Oct 07, 2024

Boulder’s OnKure goes public with merger; key drug trial underway - Boulder Daily Camera

Oct 07, 2024
pulisher
Oct 07, 2024

OnKure and Reneo Pharmaceuticals complete merger - Pharmaceutical Technology

Oct 07, 2024
pulisher
Oct 07, 2024

Galapagos investor gets board seat; OnKure completes merger with Reneo - Endpoints News

Oct 07, 2024
pulisher
Oct 05, 2024

Reneo Pharmaceuticals stockholders approval merger with OnKure - TipRanks

Oct 05, 2024
pulisher
Oct 04, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - StockTitan

Oct 04, 2024
pulisher
Oct 04, 2024

Reneo stockholders approve merger with OnKure - MSN

Oct 04, 2024
pulisher
Oct 02, 2024

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure - GlobeNewswire

Oct 02, 2024
pulisher
Sep 22, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - AOL

Sep 22, 2024
pulisher
Sep 17, 2024

Here's Why Everyone's Talking About Summit Therapeutics - AOL

Sep 17, 2024
pulisher
Sep 10, 2024

Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com

Sep 10, 2024
pulisher
Aug 13, 2024

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results - Yahoo Finance

Aug 13, 2024
pulisher
Jul 26, 2024

OnKure hires ex-Pfizer research leader as chief scientific officer - BizWest

Jul 26, 2024
pulisher
Jun 24, 2024

OnKure Therapeutics - The Pharma Letter

Jun 24, 2024
pulisher
Jun 24, 2024

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc.RPHM - PR Newswire

Jun 24, 2024
pulisher
Jun 19, 2024

OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary - GlobeNewswire

Jun 19, 2024
pulisher
May 28, 2024

Reneo Set to Close After Test Failure - Orange County Business Journal

May 28, 2024
pulisher
May 17, 2024

Public Equity Report: Erasca reboots, Telix plans NASDAQ listing - BioCentury

May 17, 2024
pulisher
May 15, 2024

Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger - Wilson Sonsini

May 15, 2024
pulisher
May 14, 2024

Reneo Pharma to merge with OnKure - The Pharma Letter

May 14, 2024
pulisher
May 13, 2024

With first drug trial underway, OnKure inks merger with Reneo Pharma to go public - BizWest

May 13, 2024
pulisher
Apr 16, 2024

Seven biotech companies climbing their way up in Colorado - Labiotech.eu

Apr 16, 2024
pulisher
Jan 08, 2024

HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Jan 08, 2024
pulisher
Dec 20, 2023

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Dec 20, 2023
pulisher
May 26, 2023

The Week’s 10 Biggest Funding Rounds: Anthropic Generates Another Huge Round, Biotech Has Big Week - Crunchbase News

May 26, 2023
pulisher
May 23, 2023

OnKure Therapeutics Announces $54 Million Series C Financing - GlobeNewswire

May 23, 2023
pulisher
Feb 28, 2023

2023 Destination Startup® drives investment in intermountain west university innovations - University of Colorado Boulder

Feb 28, 2023

Onkure Therapeutics Inc (OKUR) 재무 분석

Onkure Therapeutics Inc (OKUR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Onkure Therapeutics Inc 주식 (OKUR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Leonard Braden Michael
10% Owner
Sep 24 '24
Buy
1.41
29,600
41,866
3,388,649
Leonard Braden Michael
10% Owner
Sep 17 '24
Buy
1.36
55,300
75,108
3,358,243
Leonard Braden Michael
10% Owner
Sep 18 '24
Buy
1.40
806
1,128
3,359,049
Leonard Braden Michael
10% Owner
Sep 16 '24
Buy
1.37
172,747
236,871
3,302,943
Leonard Braden Michael
10% Owner
Sep 13 '24
Buy
1.31
150,000
196,950
3,130,196
Leonard Braden Michael
10% Owner
Sep 12 '24
Buy
1.40
36,176
50,523
2,980,196
Leonard Braden Michael
10% Owner
Aug 13 '24
Buy
1.39
171,339
238,590
2,843,533
Leonard Braden Michael
10% Owner
Aug 14 '24
Buy
1.41
100,487
142,008
2,944,020
Leonard Braden Michael
10% Owner
May 14 '24
Buy
1.54
414,281
639,578
2,672,194
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
자본화:     |  볼륨(24시간):